| scholarly article | Q13442814 |
| P50 | author | Naoki Iwanaga | Q82180977 |
| Taiga Miyazaki | Q88502855 | ||
| Yoshitsugu Miyazaki | Q103828969 | ||
| Shigeru Kohno | Q104013331 | ||
| Koichi Izumikawa | Q109648459 | ||
| Hiroshi Mukae | Q114454285 | ||
| Kazuhiro OSHIMA | Q58351882 | ||
| P2093 | author name string | Koji Takemoto | |
| Shigeki Nakamura | |||
| Kastunori Yanagihara | |||
| P2860 | cites work | In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae | Q87844618 |
| [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2012] | Q95413997 | ||
| Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 | ||
| Carbapenems | Q28286055 | ||
| Healthcare-Associated Pneumonia Does Not Accurately Identify Potentially Resistant Pathogens: A Systematic Review and Meta-Analysis | Q29543747 | ||
| Antibiotic stewardship in the intensive care unit | Q30408712 | ||
| Antimicrobial stewardship programs in health care systems | Q34097674 | ||
| Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis | Q34445159 | ||
| Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model | Q34596344 | ||
| Pharmacokinetic and pharmacodynamic models of the antistaphylococcal effects of meropenem and cloxacillin in vitro and in experimental infection | Q35138366 | ||
| In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii | Q35169078 | ||
| Interpretation of antibiotic concentration ratios measured in epithelial lining fluid | Q36936597 | ||
| Toll-like receptor 4 agonistic antibody promotes innate immunity against severe pneumonia induced by coinfection with influenza virus and Streptococcus pneumoniae. | Q36970228 | ||
| Emergence and spread of antibiotic resistance following exposure to antibiotics | Q37896674 | ||
| Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents | Q37927017 | ||
| Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring | Q38184203 | ||
| Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections | Q38193938 | ||
| Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study | Q38297846 | ||
| Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia | Q40675239 | ||
| In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients | Q40775853 | ||
| In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study | Q41028904 | ||
| Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems | Q41101292 | ||
| Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases | Q41112345 | ||
| Antimicrobial resistance surveillance of doripenem in China | Q41349872 | ||
| Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: Gen | Q41376087 | ||
| Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study | Q41741255 | ||
| In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011. | Q42237738 | ||
| Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients | Q42276769 | ||
| Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem | Q44601141 | ||
| Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. | Q45981762 | ||
| Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. | Q46019540 | ||
| The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis | Q46763845 | ||
| Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients | Q46989475 | ||
| Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. | Q47646856 | ||
| Lipopolysaccharide Induces Mucus Cell Metaplasia in Mouse Lung. | Q50507290 | ||
| Antibiotic resistance threats in the United States: stepping back from the brink | Q64125219 | ||
| The entry of meropenem into human macrophages and its immunomodulating activity | Q72287397 | ||
| Prevention of resistance: a goal for dose selection for antimicrobial agents | Q78757931 | ||
| In vitro effect of subinhibitory concentrations of ceftazidime and meropenem on the serum sensitivity of Pseudomonas aeruginosa strains | Q80542009 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pneumonia | Q12192 |
| Pseudomonas aeruginosa | Q31856 | ||
| meropenem | Q421670 | ||
| P577 | publication date | 2016-12-27 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa | |
| P478 | volume | 61 |
| Q61805091 | Variation in Mutant Prevention Concentrations | cites work | P2860 |
Search more.